<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00885365</url>
  </required_header>
  <id_info>
    <org_study_id>CMA-0631-PR-0010 Core</org_study_id>
    <nct_id>NCT00885365</nct_id>
  </id_info>
  <brief_title>A Study Comparing the Efficacy and Tolerability of Tobrineb®/Actitob®/Bramitob® Versus TOBI®</brief_title>
  <acronym>CT03 Core</acronym>
  <official_title>A Multicentre, Multinational, Open-Label, Randomised, Parallel Group Clinical Trial of Tobrineb®/Actitob®/Bramitob® (Tobramycin Solution for Nebulisation, 300mg Twice Daily in 4mL Unit Dose Vials) Compared to TOBI® in the Treatment of Patients With Cystic Fibrosis and Chronic Infection With Pseudomonas Aeruginosa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiesi Farmaceutici S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiesi Farmaceutici S.p.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of the study are to demonstrate that Tobrineb®/Actitob®/Bramitob® is
      non-inferior to TOBI® in the primary efficacy variable, forced expiratory volume in one
      second (FEV1) percent of predicted normal, and to compare the safety in participants with
      cystic fibrosis and chronic infection of the lungs with Pseudomonas aeruginosa.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline to End of the Treatment Period of Forced Expiratory Volume in 1 Second (FEV1), Expressed as Percentage of Predicted Normal</measure>
    <time_frame>Day 0 (baseline), Week 4</time_frame>
    <description>Pulmonary function measurements were performed by using a self-calibrated computer-operated pneumotochographic spirometer at all clinic visits. Because this study included both adults and children and lung volume is an age-dependent variable, reference normal FEV1 values for children were different than the reference normal values used with adult participants. Three measurements were collected and the greatest FEV1 value was recorded.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to End of Weeks 2, 4, and 8 of Forced Expiratory Volume in 1 Second (FEV1), Expressed as Percentage of Predicted Normal</measure>
    <time_frame>Day 0 (baseline), Week 2, Week 4, Week 8</time_frame>
    <description>Pulmonary function measurements were performed by using a self-calibrated computer-operated pneumotochographic spirometer at all clinic visits. Because this study included both adults and children and lung volume is an age-dependent variable, reference normal FEV1 values for children were different than the reference normal values used with adult participants. Three measurements were collected and the greatest FEV1 value was recorded. Observed values are summarized (without last observation carry forward).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to End of Weeks 2, 4, and 8 of Absolute Forced Expiratory Volume in 1 Second (FEV1)</measure>
    <time_frame>Day 0 (baseline), Week 2, Week 4, Week 8</time_frame>
    <description>Pulmonary function measurements were performed by using a self-calibrated computer-operated pneumotochographic spirometer at all clinic visits. Three measurements were collected and the greatest FEV1 value was recorded. Observed values are summarized (without last observation carry forward).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline at End of Weeks 2, 4, and 8 of Forced Vital Capacity (FVC) Expressed as Percentage of Predicted Normal</measure>
    <time_frame>Day 0 (baseline), Week 2, Week 4, Week 8</time_frame>
    <description>FVC is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. It is measured via spirometry. Because this study included both adults and children and lung volume is an age-dependent variable, reference normal FVC values for children were different than the reference normal values used with adult participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to End of Weeks 2, 4, and 8 of Absolute Forced Vital Capacity (FVC)</measure>
    <time_frame>Day 0 (baseline), Week 2, Week 4, Week 8</time_frame>
    <description>FVC is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. It is measured via spirometry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to End of Weeks 2, 4, and 8 of Forced Expiratory Flow at 25-75% of Vital Capacity (FEF 25-75%), Expressed as Percentage of Predicted Normal</measure>
    <time_frame>Day 0 (baseline), Week 2, Week 4, Week 8</time_frame>
    <description>Difference in the forced expiratory flow rate in mid-exhalation as a percent of predicted to standard values measured from baseline to weeks 2 (treated), 4 (treated), and 8 (untreated). Because this study included both adults and children and lung volume is an age-dependent variable, reference normal FEF 25-75% values for children were different than the reference normal values used with adult participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to End of Weeks 2, 4, and 8 of Forced Expiratory Flow at 25-75% of Vital Capacity (FEF 25-75%)</measure>
    <time_frame>Day 0 (baseline), Week 2, Week 4, Week 8</time_frame>
    <description>Difference in the forced expiratory flow rate in mid-exhalation measured from baseline to weeks 2 (treated), 4 (treated), and 8 (untreated).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to End of Weeks 4 and 8 in Pseudomonas Aeruginosa Log10 Bacterial Load in Sputum</measure>
    <time_frame>Day -10 to -1 (baseline), Week 4, Week 8</time_frame>
    <description>If a participant had more than one Pseudomonas aeruginosa (PA) morphotype at a given visit, and therefore more than one bacterial load value, then the bacterial load value corresponding to the highest tobramycin minimal inhibitory concentration (MIC) value regardless of the PA morphotype was used. If the tobramycin MIC value was the same for different PA morphotypes, then the bacterial load value corresponding to morphotype 1 (mucoid colony) was used. If morphotype 1 was not available, bacterial load value corresponding to morphotype 2 (dry colony) was used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimal Inhibitory Concentration Inhibiting Growth of 50% (MIC50) of Pseudomonas Aeruginosa</measure>
    <time_frame>Week 4, Week 8</time_frame>
    <description>MIC50 is the concentration of tobramycin required to inhibit 50% of Pseudomonas aeruginosa. MIC values were calculated for three different Pseudomonas aeruginosa (PA) strains:
Morphotype 1: mucoid
Morphotype 2: dry
Morphotype 3: variant
Overall MIC50 values are reported. If a participant has more than one PA morphotype at a given visit, then the highest tobramycin MIC value was used, regardless of PA morphotype. If a participant has more than one available result for each morphotype then the highest tobramycin MIC value was used. If the tobramycin MIC values are equal then the MIC value for the isolate with the highest bacterial load value was used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimal Inhibitory Concentration Inhibiting Growth of 90% (MIC90) of Pseudomonas Aeruginosa</measure>
    <time_frame>Week 4, Week 8</time_frame>
    <description>MIC90 is the concentration of tobramycin required to inhibit 90% of Pseudomonas aeruginosa. MIC values were calculated for three different Pseudomonas aeruginosa (PA) strains:
Morphotype 1: mucoid
Morphotype 2: dry
Morphotype 3: variant
Overall MIC90 values are reported. If a participant has more than one PA morphotype at a given visit, then the highest tobramycin MIC value was used, regardless of PA morphotype. If a participant has more than one available result for each morphotype then the highest tobramycin MIC value was used. If the tobramycin MIC values are equal then the MIC value for the isolate with the highest bacterial load value was used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiological Outcome Summary by Visit</measure>
    <time_frame>Day -10 to -1 (screening), Weeks 4 and 8</time_frame>
    <description>Microbiological outcomes are derived considering all P. aeruginosa (PA) morphotypes together.
Week 4 and Week 8 microbiological outcomes:
Eradication = elimination of PA
Persistence = persistence of PA detected at previous visit
Superinfection = appearance of a pathogen (other than PA) not detected at previous visit
Re-infection (week 8 only) = re-appearance of PA detected at Screening and eradicated at Week 4
Superinfection supersedes eradication. Persistence for P. aeruginosa supersedes superinfection.
Re-infection for P. aeruginosa supersedes superinfection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to End of Weeks 2, 4 and 8 in Body Weight</measure>
    <time_frame>Day 0 (baseline), Weeks 2, 4 and 8</time_frame>
    <description>Body weight was measured at all study visits as part of the physical examination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to End of Weeks 2, 4 and 8 in Body Mass Index (BMI)</measure>
    <time_frame>Day 0 (baseline), Weeks 2, 4 and 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Count of Participants With Treatment-Emergent Adverse Events (TEAEs)</measure>
    <time_frame>Day 0 to Week 8</time_frame>
    <description>Treatment-Emergent Adverse Events defined as adverse events occurring after the first intake of study treatment (or the same day).
The investigator assessed relation to study treatment as a binary question: Reasonable possibility of relatedness or no reasonable possibility of relatedness. The expression &quot;reasonable possibility of relatedness&quot; is meant to convey in general that there are facts (evidence) or arguments meant to suggest a causal relationship.
A serious AE results in death, is life-threatening, requires hospitalization or prolongation of existing inpatient hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly/birth defect or an important medical event.
The investigator rates the severity of the AE based on a three point scale: mild, moderate or severe. A severe event prevents any usual routine activity of the participant and causes severe discomfort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants With a Hearing Threshold &gt;20 Decibel in at Least One Ear</measure>
    <time_frame>Day -10 to -1 (screening), Weeks 4 and 8</time_frame>
    <description>The potential ototoxic effects (hearing loss) of tobramycin were investigated by performing audiometric tests. Participants with a loss of auditory acuity greater than the 20 decibels auditory threshold are reported.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">324</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Bramitob</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tobramycin / Bramitob administered 300mg twice a day for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TOBI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>tobramycin / TOBI administered 300mg twice a day for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tobramycin / Bramitob</intervention_name>
    <description>300mg/4ml solution, via a nebuliser, over a 4-week treatment in a twice-daily regimen</description>
    <arm_group_label>Bramitob</arm_group_label>
    <other_name>Bramitob</other_name>
    <other_name>Tobrineb</other_name>
    <other_name>Actitob</other_name>
    <other_name>Bethkis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tobramycin / TOBI</intervention_name>
    <description>300mg/5ml solution administered via nebuliser, over a 4-week treatment in a twice-daily regimen</description>
    <arm_group_label>TOBI</arm_group_label>
    <other_name>TOBI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients of either sex aged ≥ 6;

          -  Clinical diagnosis of cystic fibrosis defined as: (1)Patients preferably registered in
             the National Registry of CF (or other documents depending on country legislation); (2)
             Evidence of two or more typical pulmonary clinical features observed in CF, e.g.,
             persistent colonization/infection with typical CF pathogens, chronic cough and sputum
             production, persistent chest radiography abnormalities, airway obstruction, nasal
             polyps and/or digital clubbing;

          -  Positive response in the standard sweat test (sweat chloride concentration ≥ 60 mmol/l
             for the standard method or ≥ 80 mmol/L for a microduct technique) documented in the
             clinical records and/or gene mutation documented in the clinical records;

          -  Chronic colonization of P. aeruginosa: presence in a sputum or throat culture of a
             minimum of 2 positive samples for P. aeruginosa over the previous 12 months and/or
             presence of more than two precipitating antibodies against P. aeruginosa;

          -  Sputum containing P. aeruginosa susceptible to tobramycin (defined as a zone diameter
             ≥ 16 mm after testing with 10 µg tobramycin disk or as a minimal inhibition
             concentration based on microdilution testing system) as identified by local laboratory
             at screening visit;

          -  Forced expiratory volume in 1 sec (FEV₁) ≥ 40% and ≤ 80% of the predicted normal
             value;

          -  Written informed consent obtained by parents/legal representative according to local
             regulations) and by the patient (when appropriate).

        Exclusion Criteria:

          -  Administration of antipseudomonal antibiotic therapy by any route in the previous 4
             weeks;

          -  Evidence of impaired renal function (serum creatinine level ≥ 1.5 mg/dl);

          -  Evidence of impaired auditory function (auditory threshold in either ear above 20 dB
             at frequencies between 250 and 8000Hz);

          -  Sputum culture containing Burkholderia cepacia;

          -  Patients with end-stage lung disease, candidates for heart-lung transplantation;

          -  History of other clinically significant cardiac, renal, neurological,
             gastrointestinal, hepatic or endocrine disease related to cystic fibrosis, whose
             sequelae and/or treatment can interfere with the results of the present study;

          -  Female subjects: pregnant or with active desire to be pregnant, lactating mother or
             lack of efficient contraception in a subject with child-bearing potential (i.e.,
             contraceptive methods other than rod containing a hormone that prevents user from
             getting pregnant and that will be placed under the skin, syringes that contain a
             contraceptive hormone, combined birth control pill, i.e., such that contains two
             hormones, some intrauterine devices (IUDs) and sexual abstinence). A pregnancy test in
             urine is to be carried out in women of a fertile age at screening and at the last
             clinic visit;

          -  Known hypersensitivity to aminoglycosides;

          -  Patients with evidence of alcohol or drug abuse, likely to be not compliant with the
             study protocol or likely to be not compliant with the study treatments;

          -  Participation in another clinical trial with an investigational drug in the four weeks
             preceding the screening visit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henryk Mazurek, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinika Pneumonologii i Mukowiscydozy, Instytut Gruzlicy i Chorob Pluc w Rabce Zdroj</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centrum pro cystickou fibrosu, Pediatricka klinika UK 2.LF, Fakultní nemocnice v Motole</name>
      <address>
        <city>Praha</city>
        <zip>150 06</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHR Clemenceau</name>
      <address>
        <city>Caen</city>
        <zip>14 033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Arnaud de Villeneuve, Clinique des maladies respiratoires</name>
      <address>
        <city>Montpellier</city>
        <zip>34 295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Necker</name>
      <address>
        <city>Paris</city>
        <zip>75 015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pädiatrische Pneumologie und Allergologie, Mukovizidose-Zentrum, Zentrum für Kinderheilkunde und Jugendmedizin</name>
      <address>
        <city>GieBen</city>
        <zip>35385</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HELIOS Klinikum Krefeld, Zentrum für Kinder- und Jugendmedizin</name>
      <address>
        <city>Krefeld</city>
        <zip>47805</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fővárosi Önkormányzat Heim Pál</name>
      <address>
        <city>Budapest</city>
        <zip>H-1089</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaposi Mór Oktatókórház</name>
      <address>
        <city>Mosdos</city>
        <zip>H-7254</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szegedi Tudományegyetem Szent-Györgyi Albert Orvos- és Gyógyszerésztudományi Centrum</name>
      <address>
        <city>Szeged</city>
        <zip>H6725</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specjalistyczny ZOZ nad Matka i Dzieckiem, Poradnia Leczenia Mukowiscydozy</name>
      <address>
        <city>Gdansk</city>
        <zip>80-308</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>I Oddzial Chorob Dzieciecych, Wojewodzki Specjalistyczny Szpital Dzieciecy</name>
      <address>
        <city>Kielce</city>
        <zip>25-381</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oddzial Kliniczny Interny Dzieciecej i Alergologii, Wojewodzki Szpital Specjalistyczny</name>
      <address>
        <city>Lodz</city>
        <zip>93-513</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dzieciecy Szpital Kliniczny Akademii Medycznej, Klinika Chorob Pluc I Reumatologii</name>
      <address>
        <city>Lublin</city>
        <zip>20-093</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinika Pneumonologii, Alergologii Dzieciecej i Immunologii Klinicznej Szpital Kliniczny Uniwersytetu Medycznego w Poznaniu</name>
      <address>
        <city>Poznan</city>
        <zip>60-572</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinika Pneumonologii i Mukowiscydozy, Instytut Gruzlicy i Chorob Pluc w Rabce Zdroj</name>
      <address>
        <city>Rabka Zdroj</city>
        <zip>34-700</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Poradnia Mukowiscydozy Wojewodzkiej, Przychodni Specjalistycznej dla Dzieci, Szpitala Wojewodzkiego Nr 2</name>
      <address>
        <city>Rzeszow</city>
        <zip>35-301</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Various Cities</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinika Pediatrii Instytut Matki I Dziecka</name>
      <address>
        <city>Warszawa</city>
        <zip>01-211</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Medical Institution: Republican Childrens Clinical Hospital under the Ministry of Health of the Republic of Tatarstan</name>
      <address>
        <city>Kazan</city>
        <zip>420138</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Institution: Scientific Research Pulmonology Institute under the Roszdrav</name>
      <address>
        <city>Moscow</city>
        <zip>105077</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Medical Institution: Filatov Chidren's City Clinical Hospital #13</name>
      <address>
        <city>Moscow</city>
        <zip>123242</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Institution &quot;Nizhegorodskiy Research Institute of Children's Gastroenterology of Russian Medical Technologies&quot;</name>
      <address>
        <city>Nizhniy Novgorod</city>
        <zip>603950</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Medical Institution: Regional Children's Hospital Pulmonology Department</name>
      <address>
        <city>Rostov-on-Don</city>
        <zip>344085</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional State Medical Institution: Smolensk Regional Children's Clinical Hospital</name>
      <address>
        <city>Smolensk</city>
        <zip>214019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint-Petersburg State Medical Institution: City Children's Hospital of Saint Olga</name>
      <address>
        <city>St. Petersburg</city>
        <zip>194156</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Higher Educational Institution: Bashkir State Medical University under the Roszdrav</name>
      <address>
        <city>Ufa</city>
        <zip>450106</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Higher Educational Institution: Burdenko Voronezh State Medical Academy under the Roszdrav</name>
      <address>
        <city>Voronezh</city>
        <zip>394024</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minicipal Medical Institution: Children's Clinical Hospital #1</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150003</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario A Coruña (Hospital Materno-Infantil Teresa Herrera)</name>
      <address>
        <city>A Coruña</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario A Coruña</name>
      <address>
        <city>A Coruña</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Corporació Sanitaria Parc Tauli</name>
      <address>
        <city>Sabadell</city>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ntra Sra. De la Candelaria</name>
      <address>
        <city>Santa Cruz de Tenerife</city>
        <zip>38010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Miguel Servet (Children)</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dnipropetrovsk City Children Clinical Hospital # 2</name>
      <address>
        <city>Dnipropetrovsk</city>
        <zip>49101</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Donetsk Regional Children Clinical Hospital</name>
      <address>
        <city>Donetsk</city>
        <zip>83052</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kriviy Rig City Clinical Hospital # 8</name>
      <address>
        <city>Kriviy Rig</city>
        <zip>50047</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Phthysiology and Pulmonology n.a., F.G.Yanovskiy of the Academy of Medical Science of Ukraine</name>
      <address>
        <city>Kyiv</city>
        <zip>03680</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Pediatrics, Obstetrics and Gynecology of the Academy of Medical Science of Ukraine</name>
      <address>
        <city>Kyiv</city>
        <zip>04050</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lviv Regional Children Specialized Clinical Hospital</name>
      <address>
        <city>Lviv</city>
        <zip>79035</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odesa Regional Children Clinical Hospital</name>
      <address>
        <city>Odesa</city>
        <zip>65031</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Simferopol Central District Clinical Hospital</name>
      <address>
        <city>Simferopol</city>
        <zip>95033</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zaporizhya Regional Clinical Children Hospital</name>
      <address>
        <city>Zaporizhya</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Ukraine</country>
  </location_countries>
  <results_reference>
    <citation>Mazurek H, Chiron R, Kucerova T, Geidel C, Bolbas K, Chuchalin A, Blanco-Aparicio M, Santoro D, Varoli G, Zibellini M, Cicirello HG, Antipkin YG. Long-term efficacy and safety of aerosolized tobramycin 300 mg/4 ml in cystic fibrosis. Pediatr Pulmonol. 2014 Nov;49(11):1076-89. doi: 10.1002/ppul.22989. Epub 2014 Jan 24.</citation>
    <PMID>24464974</PMID>
  </results_reference>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 20, 2009</study_first_submitted>
  <study_first_submitted_qc>April 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2009</study_first_posted>
  <results_first_submitted>May 14, 2014</results_first_submitted>
  <results_first_submitted_qc>June 19, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 20, 2014</results_first_posted>
  <last_update_submitted>June 19, 2014</last_update_submitted>
  <last_update_submitted_qc>June 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cystic fibrosis</keyword>
  <keyword>P. aeruginosa</keyword>
  <keyword>tobramycin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobramycin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>406 participants screened, 324 participants randomized</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Bramitob</title>
          <description>tobramycin / Bramitob administered 300mg twice a day for 4 weeks</description>
        </group>
        <group group_id="P2">
          <title>TOBI</title>
          <description>tobramycin / TOBI administered 300mg twice a day for 4 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>4 Weeks ON Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="159"/>
                <participants group_id="P2" count="165"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Intent-to-Treat Population</title>
              <participants_list>
                <participants group_id="P1" count="158">Participants who took 1 dose of study medication and had baseline and at least 1 post-treatment FEV1</participants>
                <participants group_id="P2" count="163"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Population</title>
              <participants_list>
                <participants group_id="P1" count="156">Nine participants randomized to Bramitob were administered TOBI.</participants>
                <participants group_id="P2" count="168">Six participants randomized to TOBI were administered Bramitob</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="155"/>
                <participants group_id="P2" count="159"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>4 Weeks OFF Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="155"/>
                <participants group_id="P2" count="159"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="155"/>
                <participants group_id="P2" count="159"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Population</population>
      <group_list>
        <group group_id="B1">
          <title>Bramitob</title>
          <description>tobramycin / Bramitob administered 300mg twice a day for 4 weeks</description>
        </group>
        <group group_id="B2">
          <title>TOBI</title>
          <description>tobramycin / TOBI administered 300mg twice a day for 4 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="156"/>
            <count group_id="B2" value="168"/>
            <count group_id="B3" value="324"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15.95" spread="6.74"/>
                    <measurement group_id="B2" value="15.74" spread="7.24"/>
                    <measurement group_id="B3" value="15.84" spread="6.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>6-12 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>13-17 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 17 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                    <measurement group_id="B2" value="83"/>
                    <measurement group_id="B3" value="167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="85"/>
                    <measurement group_id="B3" value="157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="156"/>
                    <measurement group_id="B2" value="168"/>
                    <measurement group_id="B3" value="324"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>centimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="153.05" spread="17.31"/>
                    <measurement group_id="B2" value="153.41" spread="19.88"/>
                    <measurement group_id="B3" value="153.24" spread="18.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.64" spread="14.92"/>
                    <measurement group_id="B2" value="43.81" spread="16.39"/>
                    <measurement group_id="B3" value="43.25" spread="15.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kilograms/meters^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17.55" spread="3.12"/>
                    <measurement group_id="B2" value="17.79" spread="3.32"/>
                    <measurement group_id="B3" value="17.68" spread="3.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time from diagnosis of chronic colonization of P. aeruginosa</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.27" spread="4.22"/>
                    <measurement group_id="B2" value="2.36" spread="4.23"/>
                    <measurement group_id="B3" value="2.31" spread="4.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time from first Cystic Fibrosis diagnosis</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.16" spread="6.13"/>
                    <measurement group_id="B2" value="11.74" spread="6.55"/>
                    <measurement group_id="B3" value="11.94" spread="6.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tobramycin Minimal Inhibitory Concentration (MIC) value</title>
          <description>MIC is the lowest concentration of tobramycin that completely inhibits visible growth of a micro-organism.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;16 mcg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="143"/>
                    <measurement group_id="B2" value="159"/>
                    <measurement group_id="B3" value="302"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=16 mcg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Forced Expiratory Volume in 1 second (FEV1)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;50 % predicted</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=50 % predicted</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="119"/>
                    <measurement group_id="B2" value="130"/>
                    <measurement group_id="B3" value="249"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Use of rhDNase</title>
          <description>Baseline use of rhDNase is set to 'Yes' if a patient has used rhDNase on the same date or within the 10 days prior to start of study drug administration. If the timing of rhDNase use cannot be identified because of missing date, then the use of rhDNase at baseline is considered as 'Yes'.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="110"/>
                    <measurement group_id="B2" value="119"/>
                    <measurement group_id="B3" value="229"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to End of the Treatment Period of Forced Expiratory Volume in 1 Second (FEV1), Expressed as Percentage of Predicted Normal</title>
        <description>Pulmonary function measurements were performed by using a self-calibrated computer-operated pneumotochographic spirometer at all clinic visits. Because this study included both adults and children and lung volume is an age-dependent variable, reference normal FEV1 values for children were different than the reference normal values used with adult participants. Three measurements were collected and the greatest FEV1 value was recorded.</description>
        <time_frame>Day 0 (baseline), Week 4</time_frame>
        <population>Intent-to-Treat (ITT) Population, Last Observation Carried Forward (LOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>Bramitob</title>
            <description>tobramycin / Bramitob administered 300mg twice a day for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>TOBI</title>
            <description>tobramycin / TOBI administered 300mg twice a day for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to End of the Treatment Period of Forced Expiratory Volume in 1 Second (FEV1), Expressed as Percentage of Predicted Normal</title>
          <description>Pulmonary function measurements were performed by using a self-calibrated computer-operated pneumotochographic spirometer at all clinic visits. Because this study included both adults and children and lung volume is an age-dependent variable, reference normal FEV1 values for children were different than the reference normal values used with adult participants. Three measurements were collected and the greatest FEV1 value was recorded.</description>
          <population>Intent-to-Treat (ITT) Population, Last Observation Carried Forward (LOCF)</population>
          <units>percentage predicted FEV1</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.99" spread="9.52"/>
                    <measurement group_id="O2" value="7.51" spread="9.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Based on previous studies, the difference between reference and placebo after 4-week treatment is assumed to be about 12% and the non-inferiority margin safely placed at 4.5%. With a between-patient SD of 13.5% and estimated difference between treatments of zero, sample size of 143 per group allows a 80% power to show the non-inferiority of Bramitob® versus TOBI®. Accounting for an expected dropout rate of 11%, a minimum of 160 participants per group is required.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority is shown if the lower limit of the two-sided 95% confidence interval is above the non-inferiority margin set at -4.5%.</non_inferiority_desc>
            <p_value>0.640</p_value>
            <method>ANCOVA</method>
            <param_type>difference of least square means</param_type>
            <param_value>-0.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.58</ci_lower_limit>
            <ci_upper_limit>1.59</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to End of Weeks 2, 4, and 8 of Forced Expiratory Volume in 1 Second (FEV1), Expressed as Percentage of Predicted Normal</title>
        <description>Pulmonary function measurements were performed by using a self-calibrated computer-operated pneumotochographic spirometer at all clinic visits. Because this study included both adults and children and lung volume is an age-dependent variable, reference normal FEV1 values for children were different than the reference normal values used with adult participants. Three measurements were collected and the greatest FEV1 value was recorded. Observed values are summarized (without last observation carry forward).</description>
        <time_frame>Day 0 (baseline), Week 2, Week 4, Week 8</time_frame>
        <population>Intent-to-Treat (ITT) Population, observed values. Differences in number of participants analyzed to the ITT population represent participants who missed visits, or failed to take the FEV1 test.</population>
        <group_list>
          <group group_id="O1">
            <title>Bramitob</title>
            <description>tobramycin / Bramitob administered 300mg twice a day for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>TOBI</title>
            <description>tobramycin / TOBI administered 300mg twice a day for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to End of Weeks 2, 4, and 8 of Forced Expiratory Volume in 1 Second (FEV1), Expressed as Percentage of Predicted Normal</title>
          <description>Pulmonary function measurements were performed by using a self-calibrated computer-operated pneumotochographic spirometer at all clinic visits. Because this study included both adults and children and lung volume is an age-dependent variable, reference normal FEV1 values for children were different than the reference normal values used with adult participants. Three measurements were collected and the greatest FEV1 value was recorded. Observed values are summarized (without last observation carry forward).</description>
          <population>Intent-to-Treat (ITT) Population, observed values. Differences in number of participants analyzed to the ITT population represent participants who missed visits, or failed to take the FEV1 test.</population>
          <units>percentage predicted FEV1</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 [n=158, 163]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.70" spread="9.99"/>
                    <measurement group_id="O2" value="6.93" spread="9.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 [N=155, 161]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.10" spread="9.57"/>
                    <measurement group_id="O2" value="7.63" spread="9.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 [n=155, 159]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.47" spread="11.88"/>
                    <measurement group_id="O2" value="5.37" spread="11.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to End of Weeks 2, 4, and 8 of Absolute Forced Expiratory Volume in 1 Second (FEV1)</title>
        <description>Pulmonary function measurements were performed by using a self-calibrated computer-operated pneumotochographic spirometer at all clinic visits. Three measurements were collected and the greatest FEV1 value was recorded. Observed values are summarized (without last observation carry forward).</description>
        <time_frame>Day 0 (baseline), Week 2, Week 4, Week 8</time_frame>
        <population>Intent-to-Treat (ITT) Population, observed values. Differences in number of participants analyzed to the ITT population represent participants who missed visits, or failed to take the FEV1 test.</population>
        <group_list>
          <group group_id="O1">
            <title>Bramitob</title>
            <description>tobramycin / Bramitob administered 300mg twice a day for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>TOBI</title>
            <description>tobramycin / TOBI administered 300mg twice a day for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to End of Weeks 2, 4, and 8 of Absolute Forced Expiratory Volume in 1 Second (FEV1)</title>
          <description>Pulmonary function measurements were performed by using a self-calibrated computer-operated pneumotochographic spirometer at all clinic visits. Three measurements were collected and the greatest FEV1 value was recorded. Observed values are summarized (without last observation carry forward).</description>
          <population>Intent-to-Treat (ITT) Population, observed values. Differences in number of participants analyzed to the ITT population represent participants who missed visits, or failed to take the FEV1 test.</population>
          <units>liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 [n=158, 163]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" spread="0.27"/>
                    <measurement group_id="O2" value="0.19" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 [n=155, 161]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" spread="0.29"/>
                    <measurement group_id="O2" value="0.22" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 [n=155,159]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" spread="0.33"/>
                    <measurement group_id="O2" value="0.16" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis for Week 4</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.634</p_value>
            <method>ANCOVA</method>
            <param_type>difference of least square means</param_type>
            <param_value>-0.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.08</ci_lower_limit>
            <ci_upper_limit>0.05</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline at End of Weeks 2, 4, and 8 of Forced Vital Capacity (FVC) Expressed as Percentage of Predicted Normal</title>
        <description>FVC is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. It is measured via spirometry. Because this study included both adults and children and lung volume is an age-dependent variable, reference normal FVC values for children were different than the reference normal values used with adult participants.</description>
        <time_frame>Day 0 (baseline), Week 2, Week 4, Week 8</time_frame>
        <population>Intent-to-Treat (ITT) Population, observed values. Differences in number of participants analyzed to the ITT population represent participants who missed visits, or failed to take the FVC test.</population>
        <group_list>
          <group group_id="O1">
            <title>Bramitob</title>
            <description>tobramycin / Bramitob administered 300mg twice a day for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>TOBI</title>
            <description>tobramycin / TOBI administered 300mg twice a day for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline at End of Weeks 2, 4, and 8 of Forced Vital Capacity (FVC) Expressed as Percentage of Predicted Normal</title>
          <description>FVC is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. It is measured via spirometry. Because this study included both adults and children and lung volume is an age-dependent variable, reference normal FVC values for children were different than the reference normal values used with adult participants.</description>
          <population>Intent-to-Treat (ITT) Population, observed values. Differences in number of participants analyzed to the ITT population represent participants who missed visits, or failed to take the FVC test.</population>
          <units>percentage predicted FVC</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="156"/>
                <count group_id="O2" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 [n=156, 163]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.36" spread="10.81"/>
                    <measurement group_id="O2" value="5.36" spread="10.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 [n=153, 161]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.83" spread="10.05"/>
                    <measurement group_id="O2" value="5.58" spread="10.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 [n=153,159]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.70" spread="12.30"/>
                    <measurement group_id="O2" value="5.04" spread="12.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis for Week 4</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.630</p_value>
            <method>ANCOVA</method>
            <param_type>difference of least square means</param_type>
            <param_value>-0.55</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.78</ci_lower_limit>
            <ci_upper_limit>1.69</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to End of Weeks 2, 4, and 8 of Absolute Forced Vital Capacity (FVC)</title>
        <description>FVC is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. It is measured via spirometry.</description>
        <time_frame>Day 0 (baseline), Week 2, Week 4, Week 8</time_frame>
        <population>Intent-to-Treat (ITT) Population, observed values. Differences in number of participants analyzed to the ITT population represent participants who missed visits, or failed to take the FVC test.</population>
        <group_list>
          <group group_id="O1">
            <title>Bramitob</title>
            <description>tobramycin / Bramitob administered 300mg twice a day for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>TOBI</title>
            <description>tobramycin / TOBI administered 300mg twice a day for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to End of Weeks 2, 4, and 8 of Absolute Forced Vital Capacity (FVC)</title>
          <description>FVC is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. It is measured via spirometry.</description>
          <population>Intent-to-Treat (ITT) Population, observed values. Differences in number of participants analyzed to the ITT population represent participants who missed visits, or failed to take the FVC test.</population>
          <units>liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="156"/>
                <count group_id="O2" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 [n=156, 163]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14" spread="0.34"/>
                    <measurement group_id="O2" value="0.16" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 [n=153, 161]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" spread="0.34"/>
                    <measurement group_id="O2" value="0.18" spread="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 [n=153,159]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10" spread="0.38"/>
                    <measurement group_id="O2" value="0.16" spread="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis for Week 4</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.693</p_value>
            <method>ANCOVA</method>
            <param_type>difference of least square means</param_type>
            <param_value>-0.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.09</ci_lower_limit>
            <ci_upper_limit>0.06</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to End of Weeks 2, 4, and 8 of Forced Expiratory Flow at 25-75% of Vital Capacity (FEF 25-75%), Expressed as Percentage of Predicted Normal</title>
        <description>Difference in the forced expiratory flow rate in mid-exhalation as a percent of predicted to standard values measured from baseline to weeks 2 (treated), 4 (treated), and 8 (untreated). Because this study included both adults and children and lung volume is an age-dependent variable, reference normal FEF 25-75% values for children were different than the reference normal values used with adult participants.</description>
        <time_frame>Day 0 (baseline), Week 2, Week 4, Week 8</time_frame>
        <population>Intent-to-Treat (ITT) Population, observed values. Differences in number of participants analyzed to the ITT population represent participants who missed visits, or failed to take the FEF 25-75% test.</population>
        <group_list>
          <group group_id="O1">
            <title>Bramitob</title>
            <description>tobramycin / Bramitob administered 300mg twice a day for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>TOBI</title>
            <description>tobramycin / TOBI administered 300mg twice a day for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to End of Weeks 2, 4, and 8 of Forced Expiratory Flow at 25-75% of Vital Capacity (FEF 25-75%), Expressed as Percentage of Predicted Normal</title>
          <description>Difference in the forced expiratory flow rate in mid-exhalation as a percent of predicted to standard values measured from baseline to weeks 2 (treated), 4 (treated), and 8 (untreated). Because this study included both adults and children and lung volume is an age-dependent variable, reference normal FEF 25-75% values for children were different than the reference normal values used with adult participants.</description>
          <population>Intent-to-Treat (ITT) Population, observed values. Differences in number of participants analyzed to the ITT population represent participants who missed visits, or failed to take the FEF 25-75% test.</population>
          <units>percentage predicted FEF 25-75%</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="156"/>
                <count group_id="O2" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 [n=156, 162]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.30" spread="17.07"/>
                    <measurement group_id="O2" value="8.57" spread="19.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 [n=154, 159]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.44" spread="15.17"/>
                    <measurement group_id="O2" value="9.32" spread="17.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 [n=154,158]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.05" spread="19.59"/>
                    <measurement group_id="O2" value="6.41" spread="20.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis for Week 4</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.777</p_value>
            <method>ANCOVA</method>
            <param_type>difference of least square means</param_type>
            <param_value>0.51</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.06</ci_lower_limit>
            <ci_upper_limit>4.09</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to End of Weeks 2, 4, and 8 of Forced Expiratory Flow at 25-75% of Vital Capacity (FEF 25-75%)</title>
        <description>Difference in the forced expiratory flow rate in mid-exhalation measured from baseline to weeks 2 (treated), 4 (treated), and 8 (untreated).</description>
        <time_frame>Day 0 (baseline), Week 2, Week 4, Week 8</time_frame>
        <population>Intent-to-Treat (ITT) Population, observed values. Differences in number of participants analyzed to the ITT population represent participants who missed visits, or failed to take the FEF 25-75% test.</population>
        <group_list>
          <group group_id="O1">
            <title>Bramitob</title>
            <description>tobramycin / Bramitob administered 300mg twice a day for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>TOBI</title>
            <description>tobramycin / TOBI administered 300mg twice a day for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to End of Weeks 2, 4, and 8 of Forced Expiratory Flow at 25-75% of Vital Capacity (FEF 25-75%)</title>
          <description>Difference in the forced expiratory flow rate in mid-exhalation measured from baseline to weeks 2 (treated), 4 (treated), and 8 (untreated).</description>
          <population>Intent-to-Treat (ITT) Population, observed values. Differences in number of participants analyzed to the ITT population represent participants who missed visits, or failed to take the FEF 25-75% test.</population>
          <units>liters/second</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="156"/>
                <count group_id="O2" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 [n=156, 162]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.32" spread="0.50"/>
                    <measurement group_id="O2" value="0.28" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 [n=154, 159]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.34" spread="0.48"/>
                    <measurement group_id="O2" value="0.29" spread="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 [n=154,158]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.28" spread="0.57"/>
                    <measurement group_id="O2" value="0.21" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis for Week 4</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.505</p_value>
            <method>ANCOVA</method>
            <param_type>difference of least square means</param_type>
            <param_value>0.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.08</ci_lower_limit>
            <ci_upper_limit>0.15</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to End of Weeks 4 and 8 in Pseudomonas Aeruginosa Log10 Bacterial Load in Sputum</title>
        <description>If a participant had more than one Pseudomonas aeruginosa (PA) morphotype at a given visit, and therefore more than one bacterial load value, then the bacterial load value corresponding to the highest tobramycin minimal inhibitory concentration (MIC) value regardless of the PA morphotype was used. If the tobramycin MIC value was the same for different PA morphotypes, then the bacterial load value corresponding to morphotype 1 (mucoid colony) was used. If morphotype 1 was not available, bacterial load value corresponding to morphotype 2 (dry colony) was used.</description>
        <time_frame>Day -10 to -1 (baseline), Week 4, Week 8</time_frame>
        <population>Intent-to-Treat (ITT) Population; At Week 4, six Bramitob patients and seven TOBI patients were missing sputum samples. At Week 8, 11 Bramitob patients and 16 TOBI patients were missing sputum samples.</population>
        <group_list>
          <group group_id="O1">
            <title>Bramitob</title>
            <description>tobramycin / Bramitob administered 300mg twice a day for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>TOBI</title>
            <description>tobramycin / TOBI administered 300mg twice a day for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to End of Weeks 4 and 8 in Pseudomonas Aeruginosa Log10 Bacterial Load in Sputum</title>
          <description>If a participant had more than one Pseudomonas aeruginosa (PA) morphotype at a given visit, and therefore more than one bacterial load value, then the bacterial load value corresponding to the highest tobramycin minimal inhibitory concentration (MIC) value regardless of the PA morphotype was used. If the tobramycin MIC value was the same for different PA morphotypes, then the bacterial load value corresponding to morphotype 1 (mucoid colony) was used. If morphotype 1 was not available, bacterial load value corresponding to morphotype 2 (dry colony) was used.</description>
          <population>Intent-to-Treat (ITT) Population; At Week 4, six Bramitob patients and seven TOBI patients were missing sputum samples. At Week 8, 11 Bramitob patients and 16 TOBI patients were missing sputum samples.</population>
          <units>colony forming units/gram</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4 [n=152, 156]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.14" spread="2.41"/>
                    <measurement group_id="O2" value="-2.07" spread="2.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 [n=147, 147]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.72" spread="2.17"/>
                    <measurement group_id="O2" value="-0.87" spread="2.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis of Week 4 data</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.820</p_value>
            <p_value_desc>A priori threshold for statistical significance is &lt;= 0.050.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>treatment and country are fixed effects and baseline log10 bacterial load (CFU/g) value is a covariate</method_desc>
            <param_type>difference of least square means</param_type>
            <param_value>0.04</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.18</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.31</ci_lower_limit>
            <ci_upper_limit>0.39</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Minimal Inhibitory Concentration Inhibiting Growth of 50% (MIC50) of Pseudomonas Aeruginosa</title>
        <description>MIC50 is the concentration of tobramycin required to inhibit 50% of Pseudomonas aeruginosa. MIC values were calculated for three different Pseudomonas aeruginosa (PA) strains:
Morphotype 1: mucoid
Morphotype 2: dry
Morphotype 3: variant
Overall MIC50 values are reported. If a participant has more than one PA morphotype at a given visit, then the highest tobramycin MIC value was used, regardless of PA morphotype. If a participant has more than one available result for each morphotype then the highest tobramycin MIC value was used. If the tobramycin MIC values are equal then the MIC value for the isolate with the highest bacterial load value was used.</description>
        <time_frame>Week 4, Week 8</time_frame>
        <population>Intent-to-Treat (ITT) Population</population>
        <group_list>
          <group group_id="O1">
            <title>Bramitob</title>
            <description>tobramycin / Bramitob administered 300mg twice a day for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>TOBI</title>
            <description>tobramycin / TOBI administered 300mg twice a day for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Minimal Inhibitory Concentration Inhibiting Growth of 50% (MIC50) of Pseudomonas Aeruginosa</title>
          <description>MIC50 is the concentration of tobramycin required to inhibit 50% of Pseudomonas aeruginosa. MIC values were calculated for three different Pseudomonas aeruginosa (PA) strains:
Morphotype 1: mucoid
Morphotype 2: dry
Morphotype 3: variant
Overall MIC50 values are reported. If a participant has more than one PA morphotype at a given visit, then the highest tobramycin MIC value was used, regardless of PA morphotype. If a participant has more than one available result for each morphotype then the highest tobramycin MIC value was used. If the tobramycin MIC values are equal then the MIC value for the isolate with the highest bacterial load value was used.</description>
          <population>Intent-to-Treat (ITT) Population</population>
          <units>micrograms/milliliters</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4 [n=126, 134]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 [n=129, 128]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Minimal Inhibitory Concentration Inhibiting Growth of 90% (MIC90) of Pseudomonas Aeruginosa</title>
        <description>MIC90 is the concentration of tobramycin required to inhibit 90% of Pseudomonas aeruginosa. MIC values were calculated for three different Pseudomonas aeruginosa (PA) strains:
Morphotype 1: mucoid
Morphotype 2: dry
Morphotype 3: variant
Overall MIC90 values are reported. If a participant has more than one PA morphotype at a given visit, then the highest tobramycin MIC value was used, regardless of PA morphotype. If a participant has more than one available result for each morphotype then the highest tobramycin MIC value was used. If the tobramycin MIC values are equal then the MIC value for the isolate with the highest bacterial load value was used.</description>
        <time_frame>Week 4, Week 8</time_frame>
        <population>Intent-to-Treat (ITT) Population</population>
        <group_list>
          <group group_id="O1">
            <title>Bramitob</title>
            <description>tobramycin / Bramitob administered 300mg twice a day for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>TOBI</title>
            <description>tobramycin / TOBI administered 300mg twice a day for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Minimal Inhibitory Concentration Inhibiting Growth of 90% (MIC90) of Pseudomonas Aeruginosa</title>
          <description>MIC90 is the concentration of tobramycin required to inhibit 90% of Pseudomonas aeruginosa. MIC values were calculated for three different Pseudomonas aeruginosa (PA) strains:
Morphotype 1: mucoid
Morphotype 2: dry
Morphotype 3: variant
Overall MIC90 values are reported. If a participant has more than one PA morphotype at a given visit, then the highest tobramycin MIC value was used, regardless of PA morphotype. If a participant has more than one available result for each morphotype then the highest tobramycin MIC value was used. If the tobramycin MIC values are equal then the MIC value for the isolate with the highest bacterial load value was used.</description>
          <population>Intent-to-Treat (ITT) Population</population>
          <units>micrograms/milliliters</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4 [n=126, 134]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 [n=129, 128]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Microbiological Outcome Summary by Visit</title>
        <description>Microbiological outcomes are derived considering all P. aeruginosa (PA) morphotypes together.
Week 4 and Week 8 microbiological outcomes:
Eradication = elimination of PA
Persistence = persistence of PA detected at previous visit
Superinfection = appearance of a pathogen (other than PA) not detected at previous visit
Re-infection (week 8 only) = re-appearance of PA detected at Screening and eradicated at Week 4
Superinfection supersedes eradication. Persistence for P. aeruginosa supersedes superinfection.
Re-infection for P. aeruginosa supersedes superinfection.</description>
        <time_frame>Day -10 to -1 (screening), Weeks 4 and 8</time_frame>
        <population>Intent-to-Treat Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Bramitob</title>
            <description>tobramycin / Bramitob administered 300mg twice a day for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>TOBI</title>
            <description>tobramycin / TOBI administered 300mg twice a day for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Microbiological Outcome Summary by Visit</title>
          <description>Microbiological outcomes are derived considering all P. aeruginosa (PA) morphotypes together.
Week 4 and Week 8 microbiological outcomes:
Eradication = elimination of PA
Persistence = persistence of PA detected at previous visit
Superinfection = appearance of a pathogen (other than PA) not detected at previous visit
Re-infection (week 8 only) = re-appearance of PA detected at Screening and eradicated at Week 4
Superinfection supersedes eradication. Persistence for P. aeruginosa supersedes superinfection.
Re-infection for P. aeruginosa supersedes superinfection.</description>
          <population>Intent-to-Treat Population.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening: Presence of P aeruginosa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Eradication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.2"/>
                    <measurement group_id="O2" value="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Persistence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.9"/>
                    <measurement group_id="O2" value="85.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Superinfection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9"/>
                    <measurement group_id="O2" value="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Eradication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7"/>
                    <measurement group_id="O2" value="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Persistence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.9"/>
                    <measurement group_id="O2" value="83.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Superinfection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5"/>
                    <measurement group_id="O2" value="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Re-infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.8"/>
                    <measurement group_id="O2" value="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 4</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.692</p_value>
            <p_value_desc>A priori threshold for statistical significance is &lt;= 0.050.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Test controlling for country.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 8</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.128</p_value>
            <p_value_desc>A priori threshold for statistical significance is &lt;= 0.050.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Test controlling for country.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to End of Weeks 2, 4 and 8 in Body Weight</title>
        <description>Body weight was measured at all study visits as part of the physical examination.</description>
        <time_frame>Day 0 (baseline), Weeks 2, 4 and 8</time_frame>
        <population>Intent-to-Treat (ITT) Population, observed values. Two participants from both treatment arms were missing data at Week 4. Three participants from Bramitob and 4 participants from TOBI were missing data at Week 8.</population>
        <group_list>
          <group group_id="O1">
            <title>Bramitob</title>
            <description>tobramycin / Bramitob administered 300mg twice a day for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>TOBI</title>
            <description>tobramycin / TOBI administered 300mg twice a day for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to End of Weeks 2, 4 and 8 in Body Weight</title>
          <description>Body weight was measured at all study visits as part of the physical examination.</description>
          <population>Intent-to-Treat (ITT) Population, observed values. Two participants from both treatment arms were missing data at Week 4. Three participants from Bramitob and 4 participants from TOBI were missing data at Week 8.</population>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 [n=158, 163]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.24" spread="0.68"/>
                    <measurement group_id="O2" value="0.22" spread="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 [n=156, 161]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.39" spread="0.90"/>
                    <measurement group_id="O2" value="0.42" spread="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 [n=155,159]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.60" spread="1.14"/>
                    <measurement group_id="O2" value="0.53" spread="1.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to End of Weeks 2, 4 and 8 in Body Mass Index (BMI)</title>
        <time_frame>Day 0 (baseline), Weeks 2, 4 and 8</time_frame>
        <population>Intent-to-Treat (ITT) Population, observed values. Two participants from both treatment arms were missing data at Week 4. Three participants from Bramitob and 4 participants from TOBI were missing data at Week 8.</population>
        <group_list>
          <group group_id="O1">
            <title>Bramitob</title>
            <description>tobramycin / Bramitob administered 300mg twice a day for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>TOBI</title>
            <description>tobramycin / TOBI administered 300mg twice a day for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to End of Weeks 2, 4 and 8 in Body Mass Index (BMI)</title>
          <population>Intent-to-Treat (ITT) Population, observed values. Two participants from both treatment arms were missing data at Week 4. Three participants from Bramitob and 4 participants from TOBI were missing data at Week 8.</population>
          <units>kilograms/meters^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 [n=158, 163]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10" spread="0.28"/>
                    <measurement group_id="O2" value="0.10" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 [n=156, 161]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" spread="0.37"/>
                    <measurement group_id="O2" value="0.13" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 [n=155,159]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" spread="0.48"/>
                    <measurement group_id="O2" value="0.14" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Count of Participants With Treatment-Emergent Adverse Events (TEAEs)</title>
        <description>Treatment-Emergent Adverse Events defined as adverse events occurring after the first intake of study treatment (or the same day).
The investigator assessed relation to study treatment as a binary question: Reasonable possibility of relatedness or no reasonable possibility of relatedness. The expression “reasonable possibility of relatedness” is meant to convey in general that there are facts (evidence) or arguments meant to suggest a causal relationship.
A serious AE results in death, is life-threatening, requires hospitalization or prolongation of existing inpatient hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly/birth defect or an important medical event.
The investigator rates the severity of the AE based on a three point scale: mild, moderate or severe. A severe event prevents any usual routine activity of the participant and causes severe discomfort.</description>
        <time_frame>Day 0 to Week 8</time_frame>
        <population>Safety population: all randomised patients who took at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Bramitob</title>
            <description>tobramycin / Bramitob administered 300mg twice a day for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>TOBI</title>
            <description>tobramycin / TOBI administered 300mg twice a day for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Count of Participants With Treatment-Emergent Adverse Events (TEAEs)</title>
          <description>Treatment-Emergent Adverse Events defined as adverse events occurring after the first intake of study treatment (or the same day).
The investigator assessed relation to study treatment as a binary question: Reasonable possibility of relatedness or no reasonable possibility of relatedness. The expression “reasonable possibility of relatedness” is meant to convey in general that there are facts (evidence) or arguments meant to suggest a causal relationship.
A serious AE results in death, is life-threatening, requires hospitalization or prolongation of existing inpatient hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly/birth defect or an important medical event.
The investigator rates the severity of the AE based on a three point scale: mild, moderate or severe. A severe event prevents any usual routine activity of the participant and causes severe discomfort.</description>
          <population>Safety population: all randomised patients who took at least one dose of study medication</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="156"/>
                <count group_id="O2" value="168"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.4"/>
                    <measurement group_id="O2" value="28.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4"/>
                    <measurement group_id="O2" value="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8"/>
                    <measurement group_id="O2" value="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9"/>
                    <measurement group_id="O2" value="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE leading to withdrawal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6"/>
                    <measurement group_id="O2" value="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With a Hearing Threshold &gt;20 Decibel in at Least One Ear</title>
        <description>The potential ototoxic effects (hearing loss) of tobramycin were investigated by performing audiometric tests. Participants with a loss of auditory acuity greater than the 20 decibels auditory threshold are reported.</description>
        <time_frame>Day -10 to -1 (screening), Weeks 4 and 8</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Bramitob</title>
            <description>tobramycin / Bramitob administered 300mg twice a day for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>TOBI</title>
            <description>tobramycin / TOBI administered 300mg twice a day for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With a Hearing Threshold &gt;20 Decibel in at Least One Ear</title>
          <description>The potential ototoxic effects (hearing loss) of tobramycin were investigated by performing audiometric tests. Participants with a loss of auditory acuity greater than the 20 decibels auditory threshold are reported.</description>
          <population>Safety population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="156"/>
                <count group_id="O2" value="168"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9"/>
                    <measurement group_id="O2" value="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3"/>
                    <measurement group_id="O2" value="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day 0 to Week 8</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Bramitob</title>
          <description>tobramycin / Bramitob administered 300mg twice a day for 4 weeks</description>
        </group>
        <group group_id="E2">
          <title>TOBI</title>
          <description>tobramycin / TOBI administered 300mg twice a day for 4 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (13.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Cystic fibrosis lung</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (13.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="156"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Upon PI submission of publication to Sponsor, Sponsor will complete its review within 90 days after receipt. At Sponsor’s request, publication may be delayed up to 120 additional days for Sponsor to file necessary patent applications. In multicenter trials, PIs will postpone single center publications until after multicenter data publication. If no multicenter publication occurs within 12 months of trial completion, PI may publish single center results, subject to review timelines listed above.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chiesi Clinical Trials</name_or_title>
      <organization>Chiesi Farmaceutici S.p.A.</organization>
      <email>clinicaltrials_info@chiesi.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

